Our product portfolio is rapidly evolving. It consists of prescription pharmaceuticals and diagnostic tools primarily within specialised medicine. Our current focus disease areas are Urology and Osteoporosis. We continuously evaluate new products and aim at building a strong portfolio where synergies can be utilised between user groups and disease areas. This allows us to specialise and to be cost effective.
Pharmaprim provides urologists and nephrologists with a prescription pharmaceutical prescribed for prophylactic treatment of kidney and ureteral stones on a Named Patient basis in Sweden, Denmark, Norway and Finland. Physicians may request more information at firstname.lastname@example.org.
Spedra (avanafil) is a selective PDE5-inhibitor which was introduced in Denmark in July 2014. It was launched in Sweden and Norway in 2017.
Visit the Spedra product page (Swedish)
Adenuric (febuxostat) has been available in Denmark since 2011. Since April 23 2018, Adenuric is included in the Danish reimbursement scheme (generelt tilskud) to patients who have failed treatment with allopurinol or who have experienced side effects with allopurinol. Adenuric was introduced in Norway in 2017 and as of October 2017 it is reimbursed (Blå Resept) to patients who have failed therapy with allopurinol or experienced unacceptable side effects. Adenuric was also introduced in Sweden in 2017 and is reimbursed to patients where allopurinol is contraindicated or has generated side effects.
Pharmaprim and the Swiss pharmaceutical company EffRx signed an agreement in the spring of 2018 regarding the distribution and marketing of a novel product in osteoporosis which has been available in some European countries for 3 or 4 years. We plan to be able to launch in some countries in 2019.
Other disease areas
Pharmaprim continuously evaluates products targeting unmet medical needs and meeting our highly set safety and documentation standards.